Author:
Hauber Brett,Paulsen Russ,Krasa Holly B.,Vradenburg George,Comer Meryl,Callahan Leigh F.,Winfield John,Potashman Michele,Hartry Ann,Lee Daniel,Wilson Hilary,Hoffman Deborah L.,Wieberg Dan,Kremer Ian N.,Taylor Geraldine A.,Taylor James M.,Lappin Debra,Martin Allison D.,Frangiosa Terry,Biggar Virginia,Slota Christina,Romano Carla,DiBenedetti Dana B.
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference15 articles.
1. Aisen PS, Cummings J, Jack CR Jr, Morris JC, Sperling R, Frolich L, et al. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther. 2017;9(1):60. https://doi.org/10.1186/s13195-017-0283-5.
2. Insel PS, Weiner M, Mackin RS, Mormino E, Lim YY, Stomrud E, et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology. 2019;93(4):e322–33. https://doi.org/10.1212/WNL.0000000000007831.
3. Hartry A, Aldhouse NVJ, Al-Zubeidi T, Sanon M, Stefanacci RG, Knight SL. The conceptual relevance of assessment measures in patients with mild/mild-moderate Alzheimer’s disease. Alzheimers Dement (Amst). 2018;10:498–508. https://doi.org/10.1016/j.dadm.2018.07.006.
4. DiBenedetti DB, Slota C, Wronski SL, Vradenburg G, Comer M, Callahan LF, et al. Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes. Alzheimers Res Ther. 2020;12(1):90. https://doi.org/10.1186/s13195-020-00659-6.
5. Hauber B, DiBenedetti D, Vradenburg G, Callahan L, Potashman M, Krasa H, et al. Identifying what matters to people with and at risk for Alzheimer's disease and their care partners: concept elicitation and item development. Presented at the 12th Clinical Trials in Alzheimer's Disease Meeting; 4 Dec–7 Dec 2019. San Diego, California.